Effects of the somatostatin analogue, octreotide, in polycystic ovary syndrome.
In view of the association of hyperinsulinemia with elevated luteinizing hormone (LH) levels and hyperandrogenism in polycystic ovary syndrome (PCOS), the effect of octreotide was investigated in women with PCOS. Twelve amenorrheic women were treated with 100 micrograms octreotide twice a day for 7 days; 13 infertile women unresponsive to clomiphene citrate were treated either with octreotide (100 micrograms twice a day from day 1 of the menstrual cycle until corpus luteum formation) in addition to human menopausal gonadotropins (HMG) or with HMG alone. Octreotide significantly reduced the 4-hour integrated LH concentrations. LH pulse amplitude and nadir concentrations, and LH, testosterone, androstenedione, and estradiol responses to a gonadotropin-releasing hormone (GnRH) analogue in amenorrheic PCOS women. Octreotide treatment also resulted in a more "appropriate" hormonal milieu at the time of human chorionic gonadotropin (HCG) injection in the infertile women, with LH and testosterone levels being reduced while follicle-stimulating hormone (FSH) levels increased. Orderly follicular growth occurred, with one or two mature follicles being present at the time of HCG injection in cycles in which octreotide was given together with HMG. There were no cases of hyperstimulation, even in women who had previously hyperstimulated after HMG alone. Octreotide thus inhibits LH and androgen secretion and may improve ovulatory performance in infertile women with PCOS.
Prelević
G M
GM
Department of Endocrinology, Zvezdara University Medical Centre, Belgrade University School of Medicine, Yugoslavia.
Wurzburger
M I
MI
Balint-Perić
L
L
Hardiman
P
P
Okolo
S
S
Maletić
D
D
Ginsburg
J
J
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005498:Follicular Phase / Q000187:drug effects; D012739:Gonadal Steroid Hormones / Q000097:blood; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000008:administration & dosage; D015282:Octreotide / Q000008:administration & dosage*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000378:metabolism
D006063:Chorionic Gonadotropin; D012739:Gonadal Steroid Hormones; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D015282:Octreotide